Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be unused and discarded, according to a new study published in JAMA Internal Medicine. That could result in $133 million to $336 million in waste per year for Medicare, the study found.

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or lecanemab by simply introducing a new vial size that would reduce the amount of unused medication thrown away.

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims.